Search Results - "REEDER, C. B"

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma by Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M

“…The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL)…”
Get full text

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma by Witzig, T.E., Vose, J.M., Zinzani, P.L., Reeder, C.B., Buckstein, R., Polikoff, J.A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., Pietronigro, D., Ervin-Haynes, A.L., Czuczman, M.S.

“…Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of…”
Get full text

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial by Reeder, C B, Reece, D E, Kukreti, V, Chen, C, Trudel, S, Hentz, J, Noble, B, Pirooz, N A, Spong, J E, Piza, J G, Zepeda, V H J, Mikhael, J R, Leis, J F, Bergsagel, P L, Fonseca, R, Stewart, A K

“…We have studied a three-drug combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) on a 28-day cycle in the treatment of newly diagnosed…”
Get full text

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study by Zinzani, P.L., Vose, J.M., Czuczman, M.S., Reeder, C.B., Haioun, C., Polikoff, J., Tilly, H., Zhang, L., Prandi, K., Li, J., Witzig, T.E.

“…Mantle cell lymphoma (MCL) is an uncommon type of non-Hodgkin lymphoma with poor overall prognosis, requiring the development of new therapies. Lenalidomide is…”
Get full text

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy by STEWART, A. K, BERGSAGEL, P. L, WITZIG, T. E, ZELDENRUST, S. R, DINGLI, D, REEDER, C. B, ROY, V, KYLE, R. A, RAJKUMAR, S. V, FONSECA, R, GREIPP, P. R, DISPENZIERI, A, GERTZ, M. A, HAYMAN, S. R, KUMAR, S, LACY, M. Q, LUST, J. A, RUSSELL, S. J

“…Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such…”
Get full text

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study by Nowakowski, G S, LaPlant, B, Habermann, T M, Rivera, C E, Macon, W R, Inwards, D J, Micallef, I N, Johnston, P B, Porrata, L F, Ansell, S M, Klebig, R R, Reeder, C B, Witzig, T E

“…Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish…”
Get full text

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? by Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K

“…Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore…”
Get full text

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial by Ailawadhi, S, Mikhael, J R, LaPlant, B R, Laumann, K M, Kumar, S, Roy, V, Dingli, D, Bergsagel, P L, Buadi, F K, Rajkumar, S V, Fonseca, R, Gertz, M A, Kapoor, P, Sher, T, Hayman, S R, Stewart, A K, Dispenzieri, A, Kyle, R A, Gonsalves, W I, Reeder, C B, Lin, Y, Go, R S, Leung, N, Kourelis, T, Lust, J A, Russell, S J, Chanan-Khan, A A, Lacy, M Q

“…Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort…”
Get full text

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma by Witzig, T E, Laumann, K M, Lacy, M Q, Hayman, S R, Dispenzieri, A, Kumar, S, Reeder, C B, Roy, V, Lust, J A, Gertz, M A, Greipp, P R, Hassoun, H, Mandrekar, S J, Rajkumar, S V

“…Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as…”
Get full text

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique by Gertz, M A, Reeder, C B, Kyle, R A, Ansell, S M

“…Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of…”
Get full text

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials by Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R. L., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, Giovannino, Habermann, T. M., Witzig, T. E., Vitolo, U., Nowakowski, G. S.

“…Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this…”
Get full text

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib by Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A

“…This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who have limited prior exposure to…”
Get full text

A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia by TEFFERI, A, LI, C-Y, SCHAEFER, P. L, MAILLIARD, J. A, REEDER, C. B, GEYER, S. M, ALLMER, C, LEVITT, R, MICHALAK, J. C, ADDO, F, KROOK, E, WITZIG, T. E

“…In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and…”
Get full text

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation by Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V

Get full text

Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura by Harold, K L, Schlinkert, R T, Mann, D K, Reeder, C B, Noel, P, Fitch, T R, Braich, T A, Camoriano, J K

“…To assess the results of laparoscopic splenectomy as a treatment for immune thrombocytopenic purpura (ITP). We conducted a retrospective study of all patients…”
Get more information

The evolution of Hodgkin's disease and necrobiotic xanthogranuloma syndrome by Reeder, C B, Connolly, S M, Winkelmann, R K

“…We describe a woman in whom hypogammaglobulinemia and severe granulomatous cutaneous lesions had developed during childhood; subsequently, Hodgkin's disease…”
Get more information

Dissolved oxygen fluctuations in organically and inorganically fertilized walleye ( Stizostedion vitreum) hatchery ponds by Middleton, Roderick J, Reeder, Brian C

“…We compared autotroph productivity and fish production in walleye ( Stizostedion vitreum) hatchery ponds under two fertilization regimes. Three ponds were…”
Get full text

Comparison of methods to assess water column primary production in wetlands by Reeder, Brian C, Binion, Brian M

“…We compared a number of techniques to measure water column autotroph production in a shallow, hypereutrophic wetland: diurnal oxygen changes; light and dark…”
Get full text

Eosinophil-mediated bile duct stricture. A case studied by immunohistochemistry by Schlinkert, R T, de la Garza-Grahm, M, Reeder, C B, Weiland, L H, Beart, Jr, R W, Gleich, G J, Kephart, G M, de Groen, P C

“…Major basic protein accounts for the majority of the protein within the eosinophilic granule. Utilizing immunohistochemical staining for major basic protein,…”
Get more information

THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B‐CELL LYMPHOMAS by Villasboas, J.C., Reeder, C.B., Tun, H.W., Bartlett, N.L., Sharon, E., LaPlant, B., Adjei, A., Ansell, S.M.

Get full text